Browse articles from EyeWorld.org related to Demodex. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves IND for neuropathic pain drug ➤ Phase 2 preliminary efficacy and safety data for wet AMD treatment trial ➤ First-in-human data for DME, AMD therapy ➤ Study: Rapid eye stroke detection protocol helps prevent vision loss ➤ Enrollment complete for Phase 3 trial for sozinibercept ➤ ASCRS news and events
➤ Positive topline results in Phase 2a trial for treatment of MGD in patients with Demodex ➤ First patient visit in Phase 2b trial evaluating anti-TNFα for dry eye disease ➤ Smart contact lens makes progress ➤ Asset transition ➤ ASCRS news and events
Blepharitis is commonly seen by ophthalmologists. This inflammation of the eyelid margins can be acute or chronic and has a multitude of etiologies. This article gives an in-depth look at the condition, with helpful insights from two experts.
➤ FDA approves image and data management/analysis platform ➤ Results from pivotal Phase 3 trial for new Demodex treatment ➤ Trial demonstrates safety, efficacy of mydriasis-reversal drug in pediatric patients ➤ Phase 3 pivotal trial for novel dry eye disease, MGD drug candidate ➤ Phase 3 results for investigational geographic atrophy therapy ➤ New coalition supports sustainability in ophthalmology ➤ ASCRS news and events
➤ Launch of IOL made with new ‘glistening-free’ material ➤ Enrollment complete in study of mydriasis-reversing drop in a pediatric group ➤ Acquisition of electrophysiology medical device company ➤ Licensing of investigational neuroprotective drug ➤ ASCRS news and events
➤ New and updated products for cataract workflow announced ➤ FDA approves first biosimilar in ophthalmology ➤ Acquisition of gene therapy company ➤ Licensing agreement for compounds targeting Demodex mites ➤ ASCRS news and events
➤ Survey: 96% of ophthalmologists vaccinated against COVID-19 ➤ Phase 2b/3 results from trial for Demodex blepharitis ➤ Data from ongoing Phase 2a study of therapy for geographic atrophy ➤ First patient enrolled in Phase 2 study of nasal spray for neurotrophic keratopathy ➤ Next ASCRS Journal Club on July 8
➤ FDA approves new presbyopia-correcting IOL ➤ New way to evaluate sickle cell retinopathy ➤ Positive Phase 2a data on novel, topical dry eye disease drug candidate ➤ Second Phase 3 trial initiated for Demodex blepharitis treatment ➤ Large-scale, randomized controlled trial replicated with real-world data set ➤ ASCRS events
➤ FDA grants De Novo authorization for new intense pulsed light device ➤ Post-approval study requirements fulfilled for clear corneal incision sealant ➤ Interim analysis for acute adenoviral conjunctivitis drug ➤ NDA resubmission for injection to treat macular edema associated with uveitis ➤ FDA approves abbreviated NDA for glaucoma drug ➤ Study: Functional and psychosocial impact of Demodex blepharitis ➤ Next ASCRS Journal Club on May 13
Ophthalmologists are just beginning to understand how the mite causes recurrent inflammation to eyelids.